Suzanne Kyle

Newcastle University — United Kingdom

Medicine · Health Sciences

23h-index8.1kcitations75works1.72yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

PARP inhibition in cancer therapy(62), DNA Repair Mechanisms(20), Cancer therapeutics and mechanisms(10), Chemotherapy-induced cardiotoxicity and mitigation(6), Electron Spin Resonance Studies(6)

Publications75 total

Abstract 5331: Orthosteric CDK2 kinase inhibitors have a distinctive profile when compared to genetic perturbation of CDK2 in CCNE1-amplified and non-amplified tumor cell lines
Cancer Research·2025
Abstract 6588: Discovery of ASTX295, a potent, next-generation small molecule antagonist of MDM2 with differentiated pharmacokinetic profile
Cancer Research·2024· 2 cited
Abstract 3333: Targeting the MDM2-p53 interaction: Time- and concentration-dependent studies in tumor and normal human bone marrow cells reveal strategies for an enhanced therapeutic index
Cancer Research·2024· 3 cited
Data from The Clinically Active PARP Inhibitor AG014699 Ameliorates Cardiotoxicity but Does Not Enhance the Efficacy of Doxorubicin, despite Improving Tumor Perfusion and Radiation Response in Mice
2023Open Access
Supplementary Figure 1 from The Clinically Active PARP Inhibitor AG014699 Ameliorates Cardiotoxicity but Does Not Enhance the Efficacy of Doxorubicin, despite Improving Tumor Perfusion and Radiation Response in Mice
2023Open Access
Supplementary Tables 1-2 from The Clinically Active PARP Inhibitor AG014699 Ameliorates Cardiotoxicity but Does Not Enhance the Efficacy of Doxorubicin, despite Improving Tumor Perfusion and Radiation Response in Mice
2023Open Access
Supplementary Figure 1 from The Clinically Active PARP Inhibitor AG014699 Ameliorates Cardiotoxicity but Does Not Enhance the Efficacy of Doxorubicin, despite Improving Tumor Perfusion and Radiation Response in Mice
2023Open Access
Supplementary Tables 1-2 from The Clinically Active PARP Inhibitor AG014699 Ameliorates Cardiotoxicity but Does Not Enhance the Efficacy of Doxorubicin, despite Improving Tumor Perfusion and Radiation Response in Mice
2023Open Access
Data from The Clinically Active PARP Inhibitor AG014699 Ameliorates Cardiotoxicity but Does Not Enhance the Efficacy of Doxorubicin, despite Improving Tumor Perfusion and Radiation Response in Mice
2023Open Access
Supplementary Data from Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentiation <i>In vivo</i>?
2023Open Access
Data from Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial
2023Open Access
Supplementary Data from Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentiation <i>In vivo</i>?
2023Open Access
Data from Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentiation <i>In vivo</i>?
2023Open Access
Adobe PDF - MCT-06-0552--Suppl_Table_S1.pdf from Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial
2023Open Access
Data from Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentiation <i>In vivo</i>?
2023Open Access
Adobe PDF - MCT-06-0552--Suppl_Table_S1.pdf from Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial
2023Open Access
Data from Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors
2023Open Access
Supplementary Data from Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors
2023Open Access
Adobe PDF - MCT-06-0552--Suppl_Table_S2.pdf from Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial
2023Open Access
Data from Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Nicola J. Curtin(42), Huw D. Thomas(38), David R. Newell(16), Zdeněk Hostomský(15), Thomas Helleday(12), Kaye J. Williams(11), Evan A. Mulligan(11), Natalia Issaeva(10), Tatjana Djurenovic(10), Janneke E. Jaspers(10), Ivaylo Stoimenov(10), Nicholas Pedley(10), Ponnari Gottipati(10), Rafal Zur(10), Kate Sleeth(10), Vicky Chatzakos(10), Cecilia Lundin(10), Evgenia Gubanova(10), Ariena Kersbergen(10), Adrian L. Harris(10)